HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives
Executive Summary
The UK's MHRA has approved the Rx-to-OTC switch of two identical progestogen-only contraceptive pills from HRA Pharma and Maxwellia. Hana and Lovima (both 75mcg desogestrel) will be launched at the end of the month.
You may also be interested in...
Perrigo Starts Supply Chain Overhaul After Filing OTC Birth Control NDA, Launching Nasonex Switch
Along with Q2 results including reported net sales up 14.3% to $1.12bn, Perrigo announces overhaul of its supply chain expected to generate $100m to $300m in net cost savings and creation of women's health, skin care business units.
People On The Move: HRA Pharma, Hofseth BioCare, UK CHM
A round-up of the latest people moves in Europe's health and wellness markets: HRA Pharma's CEO David Wright steps down; Hofseth BioCare promotes Ødegård to lead the company; and the UK's Commission on Human Medicines appoints nine new members.
US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application
Perrigo's HRA Pharma submits to FDA on 11 July an NDA by for OTC 0.075-mg norgestrel, branded Opill, The same formulation previously was available Rx 30 years.